WO2021221482A1 - 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 - Google Patents
신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 Download PDFInfo
- Publication number
- WO2021221482A1 WO2021221482A1 PCT/KR2021/005481 KR2021005481W WO2021221482A1 WO 2021221482 A1 WO2021221482 A1 WO 2021221482A1 KR 2021005481 W KR2021005481 W KR 2021005481W WO 2021221482 A1 WO2021221482 A1 WO 2021221482A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- amino acid
- acid sequence
- protein
- group
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 174
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 167
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title claims abstract description 44
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 title claims abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 28
- 208000008589 Obesity Diseases 0.000 title claims abstract description 18
- 235000020824 obesity Nutrition 0.000 title claims abstract description 18
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 30
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 28
- 108010068086 Polyubiquitin Proteins 0.000 claims abstract description 23
- 102100037935 Polyubiquitin-C Human genes 0.000 claims abstract description 23
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 17
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 17
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 16
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 15
- 230000007882 cirrhosis Effects 0.000 claims abstract description 14
- 201000007270 liver cancer Diseases 0.000 claims abstract description 12
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 235000018102 proteins Nutrition 0.000 claims description 162
- 150000001413 amino acids Chemical group 0.000 claims description 113
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 claims description 49
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 claims description 48
- 108020003175 receptors Proteins 0.000 claims description 47
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 45
- 102000005962 receptors Human genes 0.000 claims description 44
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 37
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 37
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 34
- 102000044159 Ubiquitin Human genes 0.000 claims description 29
- 108090000848 Ubiquitin Proteins 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 17
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 235000018977 lysine Nutrition 0.000 claims description 10
- 239000004475 Arginine Substances 0.000 claims description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- 230000009977 dual effect Effects 0.000 claims description 9
- 229940044601 receptor agonist Drugs 0.000 claims description 9
- 239000000018 receptor agonist Substances 0.000 claims description 9
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 7
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 108090000901 Transferrin Proteins 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000539 dimer Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 5
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 description 81
- 108060003199 Glucagon Proteins 0.000 description 81
- 229960004666 glucagon Drugs 0.000 description 79
- 230000001052 transient effect Effects 0.000 description 78
- 210000004027 cell Anatomy 0.000 description 73
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 70
- 238000012360 testing method Methods 0.000 description 46
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 33
- 102100040918 Pro-glucagon Human genes 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 28
- 239000013642 negative control Substances 0.000 description 28
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 26
- 108010082126 Alanine transaminase Proteins 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 239000002609 medium Substances 0.000 description 22
- 239000000556 agonist Substances 0.000 description 21
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 19
- 108010019598 Liraglutide Proteins 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 18
- 229960002701 liraglutide Drugs 0.000 description 18
- 239000001488 sodium phosphate Substances 0.000 description 18
- 229910000162 sodium phosphate Inorganic materials 0.000 description 18
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 239000000872 buffer Substances 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 238000000746 purification Methods 0.000 description 17
- 238000011156 evaluation Methods 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 210000005228 liver tissue Anatomy 0.000 description 15
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 14
- 230000007863 steatosis Effects 0.000 description 14
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 108010028554 LDL Cholesterol Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000037213 diet Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 239000000546 pharmaceutical excipient Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010067125 Liver injury Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 108010057466 NF-kappa B Proteins 0.000 description 7
- 102000003945 NF-kappa B Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 230000021615 conjugation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 231100000234 hepatic damage Toxicity 0.000 description 7
- 230000008818 liver damage Effects 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 6
- 108010093061 HLA-DPA1 antigen Proteins 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000001593 cAMP accumulation Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 108010005794 dulaglutide Proteins 0.000 description 6
- 229960005175 dulaglutide Drugs 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 5
- 102100020683 Beta-klotho Human genes 0.000 description 5
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 5
- 102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 5
- 108010039343 HLA-DRB1 Chains Proteins 0.000 description 5
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 5
- 102100027441 Nucleobindin-2 Human genes 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 235000021068 Western diet Nutrition 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 238000007747 plating Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 238000007400 DNA extraction Methods 0.000 description 4
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 4
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 4
- 206010060891 General symptom Diseases 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 239000012149 elution buffer Substances 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 238000000126 in silico method Methods 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100036243 HLA class II histocompatibility antigen, DQ alpha 1 chain Human genes 0.000 description 3
- 108010086786 HLA-DQA1 antigen Proteins 0.000 description 3
- 101000684495 Homo sapiens Sentrin-specific protease 1 Proteins 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 102100023653 Sentrin-specific protease 1 Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000001789 adipocyte Anatomy 0.000 description 3
- 230000003178 anti-diabetic effect Effects 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000013229 diet-induced obese mouse Methods 0.000 description 3
- 229940125542 dual agonist Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 101100284398 Bos taurus BoLA-DQB gene Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 description 2
- 102100040890 Glucagon receptor Human genes 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 102100040482 HLA class II histocompatibility antigen, DR beta 3 chain Human genes 0.000 description 2
- 102210049245 HLA-DQA1*05:01 Human genes 0.000 description 2
- 108010061311 HLA-DRB3 Chains Proteins 0.000 description 2
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 description 2
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108010076089 accutase Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 239000013622 capto Q Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002635 electroconvulsive therapy Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 230000002962 histologic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- YEKUUBPJRPXMBM-PTCFZACGSA-N (2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S)-1-[[2-(carboxymethylamino)-2-oxoethyl]amino]-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(O)=O)C(O)=O YEKUUBPJRPXMBM-PTCFZACGSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 208000004611 Abdominal Obesity Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010065941 Central obesity Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102210012671 DPB1*01:01 Human genes 0.000 description 1
- 102210047211 DPB1*04:01 Human genes 0.000 description 1
- 102210047286 DQB1*02:01 Human genes 0.000 description 1
- 102210010092 DQB1*03:01 Human genes 0.000 description 1
- 102210047287 DQB1*03:02 Human genes 0.000 description 1
- 102210042965 DQB1*06:02 Human genes 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 description 1
- 102100028636 HLA class II histocompatibility antigen, DR beta 4 chain Human genes 0.000 description 1
- 102100028640 HLA class II histocompatibility antigen, DR beta 5 chain Human genes 0.000 description 1
- 102220440888 HLA-DQA1*03:01 Human genes 0.000 description 1
- 102210049236 HLA-DRB1*03:01 Human genes 0.000 description 1
- 108010047214 HLA-DRB1*03:01 antigen Proteins 0.000 description 1
- 108010033222 HLA-DRB1*04 antigen Proteins 0.000 description 1
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 description 1
- 102210029654 HLA-DRB1*07:01 Human genes 0.000 description 1
- 102210026621 HLA-DRB1*13 Human genes 0.000 description 1
- 102210059845 HLA-DRB1*15:01 Human genes 0.000 description 1
- 108010040960 HLA-DRB4 Chains Proteins 0.000 description 1
- 108010016996 HLA-DRB5 Chains Proteins 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000940063 Homo sapiens Ubiquitin-conjugating enzyme E2 variant 2 Proteins 0.000 description 1
- 101150046735 LEPR gene Proteins 0.000 description 1
- 101150063827 LEPROT gene Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 102100020695 Ubiquitin-conjugating enzyme E2 N Human genes 0.000 description 1
- 101710192923 Ubiquitin-conjugating enzyme E2 N Proteins 0.000 description 1
- 102100031122 Ubiquitin-conjugating enzyme E2 variant 2 Human genes 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 108091005205 cotadutide Proteins 0.000 description 1
- 229940121426 cotadutide Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 108010073571 gastric inhibitory polypeptide (1-39) Proteins 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012405 in silico analysis Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 208000018191 liver inflammation Diseases 0.000 description 1
- 235000015250 liver sausages Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000003571 reporter gene assay Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940118080 saxenda Drugs 0.000 description 1
- 108010060325 semaglutide Proteins 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000013559 triple agonist Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Definitions
- the present invention relates to a protein conjugate comprising polyubiquitin, a carrier bound to polyubiquitin, and two or more biomolecules bound to the polyubiquitin or carrier.
- the present invention relates to a pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis, fatty liver, liver fibrosis, cirrhosis, liver cancer, obesity, and diabetes, comprising a protein conjugate comprising two or more biomolecules. .
- Non-alcoholic fatty liver disease is a type of disease that shows tissue findings similar to alcoholic hepatitis even though no or little alcohol is consumed. , NAFL) to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinomas.
- NASH non-alcoholic steatohepatitis
- Nonalcoholic fatty liver disease is on the rise as the obesity and diabetic population increase, and the annual incidence rate in Korea is about 16%.
- Nonalcoholic steatohepatitis is mainly characterized by abnormal fat accumulation or deposition in the liver (hepatic steatosis), liver inflammation and liver damage or liver tissue damage (fibrosis).
- hepatic steatosis abnormal fat accumulation or deposition in the liver
- liver inflammation liver inflammation
- liver damage liver tissue damage
- fibrosis liver tissue damage
- nonalcoholic steatohepatitis there is no therapeutic agent on the market to treat nonalcoholic steatohepatitis, and due to the absence of a therapeutic agent, other metabolic syndrome drugs such as abdominal obesity, hyperlipidemia, and diabetes, for example, insulin resistance improving drugs, antioxidants (e.g., Vitamins C and E), dyslipidemia treatment agents, hepatoprotectors, etc. are used, but these are hardly considered to be direct treatments for nonalcoholic steatohepatitis.
- other metabolic syndrome drugs such as abdominal obesity, hyperlipidemia, and diabetes, for example, insulin resistance improving drugs, antioxidants (e.g., Vitamins C and E), dyslipidemia treatment agents, hepatoprotectors, etc.
- nonalcoholic steatohepatitis has the nature of a complex disease
- the licensing authorities such as the United States and Europe have set strict drug approval requirements.
- Multi-agent-based therapeutics are emerging.
- Obesity refers to a state of excess body fat, and can be defined as a health risk condition that is caused by a number of diseases, including heart disease, due to excess body fat.
- the World Health Organization (WHO) reports that there are more than 106 million overweight adults worldwide, at least 4 million are obese, and more than 2 in 3 Americans are overweight or obese (Low et al, 2009; Cooke and Bloom, 2006).
- Obese people have an increased risk of several diseases, including type 2 diabetes, hyperlipidemia, arthritis, and apnea, compared to those of normal weight, and are known to cause several types of cancer and heart disease.
- Diabetes mellitus is a metabolic disease in which high blood sugar levels persist for a long time due to insufficient insulin secretion or insulin resistance. As the blood sugar level in the body continues for a long time, glycation products invade the retina, kidneys, nerves, or large and small blood vessels throughout the body, causing chronic complications. Since diabetes is more dangerous than diabetes itself, the biggest goal in diabetes treatment today is to suppress the occurrence or progression of diabetes complications. Typical complications of diabetes include diabetic retinopathy, diabetic cataract, diabetic nephropathy, diabetic neuropathy, diabetic heart disease, diabetic osteoporosis, diabetic atherosclerosis, and the like.
- Patent Document 0001 Korean Patent Laid-Open No. 10-2016-0032699
- Patent Document 0002 Korean Patent Registration No. 10-2034607
- An object of the present invention is to provide a protein conjugate comprising polyubiquitin, a carrier bound to polyubiquitin, and two or more biomolecules bound to the polyubiquitin or carrier.
- the present invention provides a pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis (NASH), fatty liver, liver fibrosis, cirrhosis, liver cancer, obesity or diabetes, comprising a protein conjugate comprising the two or more biomolecules.
- NASH non-alcoholic steatohepatitis
- the present invention relates to non-alcoholic steatohepatitis, fatty liver, liver fibrosis, cirrhosis, liver cancer.
- An object of the present invention is to provide a pharmaceutical composition for preventing or treating obesity, or diabetes.
- the present invention includes polyubiquitin, a carrier directly bound to the polyubiquitin or a carrier bound by a linker, and a biomolecule bound directly to the polyubiquitin or carrier or bound by a linker, wherein the polyubiquitin is (i ) A lysine of ubiquitin may be substituted with arginine or alanine, but the acceptor ubiquitin includes at least one unsubstituted lysine, and (ii) a donor ubiquitin in which all lysines of ubiquitin are substituted with arginine or alanine, wherein the biomolecule is GCG, GLP-1, FGF21, GIP and IL-1RA; its analogues; GCG and GLP-1 dual receptor agonists; And it provides a protein conjugate, characterized in that two or more selected from the group consisting of GLP-1 and GIP dual receptor agonists.
- the GCG and analogs thereof may be selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 1 to 3, and preferably, the GCG analogs may be proteins consisting of the amino acid sequence of SEQ ID NO: 2 .
- the GLP-1 and analogs thereof may be selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 4 to 14, and preferably, the GLP-1 analog consists of the amino acid sequence of SEQ ID NO: 12 It may be a protein.
- the GCG and GLP-1 dual receptor agonist may be selected from the group consisting of proteins consisting of the amino acid sequences of SEQ ID NOs: 15 and 16.
- the FGF21 and analogs thereof may be selected from the group consisting of proteins consisting of the amino acid sequences of SEQ ID NOs: 17 to 21.
- the FGF21 analog may be a protein consisting of the amino acid sequence of SEQ ID NO: 20.
- the GIP and its analogs may be selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 22 to 26.
- the GIP and its analog may be a protein consisting of the amino acid sequence of SEQ ID NO: 24.
- the IL-1RA and its analogs may be selected from the group consisting of proteins consisting of the amino acid sequences of SEQ ID NOs: 27 and 28.
- the IL-1RA may be a protein consisting of the amino acid sequence of SEQ ID NO: 27.
- the polyubiquitin consists of acceptor ubiquitin in which lysines 6, 11, 27, 29, 33, and 48 are substituted with arginine at the N-terminus of ubiquitin and donor ubiquitin in which all lysines of ubiquitin are substituted with arginine.
- the polyubiquitin may be composed of the acceptor ubiquitin consisting of the amino acid sequence of SEQ ID NO: 30 and the donor ubiquitin consisting of the amino acid sequence of SEQ ID NO: 31.
- the linker may be a polypeptide consisting of an amino acid sequence in which 1 to 30 repetitions of GGGGS, EAAAK or VPPPPP are combined.
- the linker may be a polypeptide consisting of the amino acid sequence of SEQ ID NO: 29.
- the carrier is albumin, antibody fragment, scFc (single chain Fc), scFc dimer (single chain Fc-dimer), transferrin (transferrin), XTEN (genetic fusion of non-exact repeat peptide sequence), CTP ( carboxy-terminal peptide), PAS (proline-alanine-serine polymer), ELK (elastin-like peptide), HAP (homo-amino acid polymer), GLK (gelatin-like protein), PEG (polyethylene glycol), and fatty acids (fatty acid) may be selected from the group consisting of.
- the carrier may be albumin.
- the present invention provides a protein conjugate represented by the following formula.
- W, X, Y and Z are each GCG analog consisting of the amino acid sequence of SEQ ID NO: 2, GLP-1 analog consisting of the amino acid sequence of SEQ ID NO: 12, FGF21 analog consisting of the amino acid sequence of SEQ ID NO: 20, SEQ ID NO: 24
- a biomolecule selected from the group consisting of a GIP analog consisting of the amino acid sequence of ) is the donor ubiquitin consisting of the amino acid sequence of SEQ ID NO: 31, L is each independently a member or a linker, A is a carrier, Ub (A) and Ub (D) are covalently linked can
- X is a GCG analog consisting of the amino acid sequence of SEQ ID NO: 2
- Y is a GLP-1 analog consisting of the amino acid sequence of SEQ ID NO: 12
- Z is an FGF21 analog consisting of the amino acid sequence of SEQ ID NO: 20
- W may be a GIP analog consisting of the amino acid sequence of SEQ ID NO: 24 or IL-1RA consisting of the sequence of SEQ ID NO: 27.
- the linker may be a polypeptide consisting of the amino acid sequence of SEQ ID NO: 29, and the carrier may be albumin.
- the present invention provides a pharmaceutical composition for preventing or treating non-alcoholic steatohepatitis (NASH), fatty liver, liver fibrosis, cirrhosis, liver cancer, obesity or diabetes, including the protein conjugate.
- NASH non-alcoholic steatohepatitis
- fatty liver fatty liver
- liver fibrosis fatty liver
- cirrhosis cirrhosis
- liver cancer obesity or diabetes
- the present invention provides a method for preventing or treating non-alcoholic steatohepatitis (NASH), fatty liver, liver fibrosis, cirrhosis, liver cancer, obesity or diabetes, comprising administering the composition to a subject other than a human.
- NASH non-alcoholic steatohepatitis
- fatty liver fatty liver
- liver fibrosis fatty liver
- cirrhosis cirrhosis
- liver cancer obesity or diabetes
- W, X, Y and Z are each GCG analog consisting of the amino acid sequence of SEQ ID NO: 2, GLP-1 analog consisting of the amino acid sequence of SEQ ID NO: 12, FGF21 analog consisting of the amino acid sequence of SEQ ID NO: 20, the amino acid sequence of SEQ ID NO: 24 It is a biomolecule selected from the group consisting of a GIP analog consisting of and IL-1RA consisting of the amino acid sequence of SEQ ID NO: 27, Ub (A) is a receptor ubiquitin consisting of the amino acid sequence of SEQ ID NO: 30, and Ub (D) is the sequence It provides a method for producing a protein conjugate, characterized in that the donor ubiquitin consisting of the amino acid sequence of No. 31, L is a member or a linker, and A is a carrier.
- the novel protein conjugate of the present invention contains two or more biomolecules, and inhibits steatosis, inflammation, and fibrosis in the liver, thereby preventing or treating non-alcoholic steatohepatitis (NASH), fatty liver, liver fibrosis, cirrhosis or liver cancer It has an excellent effect on, and can be usefully used for the prevention or treatment of obesity or diabetic diseases.
- the protein conjugate can be maintained for a long time in the body to exert its effect for a long time, and has excellent safety by using polyubiquitin and a carrier harmless to the human body.
- Figure 2 is a schematic diagram showing the purification process of the donor protein.
- 3 and 4 show the results of purification of the donor protein through the Ni column by SDS-PAGE.
- 5 and 6 show the results of purification through His-SUMO removal of the donor protein confirmed by SDS-PAGE.
- FIG. 9 is a schematic diagram illustrating a process for preparing a protein conjugate through conjugation of an acceptor protein and a donor protein.
- 16 to 18 are graphs showing the results of cAMP accumulation assay.
- 19 is a graph showing the results of FGFR/KLB functional assay.
- 21 and 22 are graphs showing the measurement results of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse blood in an in-vivo efficacy test.
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- 23 to 26 show the results of observation of steatosis and lobular inflammation in the mouse liver tissue in the in-vivo efficacy test and the scores according to the NAS evaluation criteria.
- 27 and 28 are graphs showing the measurement results of TGT- ⁇ and triglyceride concentrations in mouse liver tissue in an in-vivo efficacy test.
- 29 and 30 are graphs showing the measurement results of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse blood in an in-vivo efficacy test.
- ALT alanine aminotransferase
- AST aspartate aminotransferase
- 31 to 34 show the results of observation of steatosis and lobular inflammation in the mouse liver tissue in the in-vivo efficacy test and scores according to the NAS evaluation criteria.
- 35 and 36 are graphs showing the measurement results of TGT- ⁇ and triglyceride concentrations in mouse liver tissue in an in-vivo efficacy test.
- TG triglycerides
- NEFA free fatty acids
- T-Chol total cholesterol
- LDL-Cholesterol low-density lipoprotein cholesterol
- HDL-Cholesterol high-density lipoprotein cholesterol in serum of diet-induced obese mice in an in-vivo efficacy test.
- 44 and 45 are graphs showing changes in body weight of type 2 diabetic mice in an in-vivo efficacy test.
- 46 and 47 are graphs showing changes in feed intake of type 2 diabetic mice in an in-vivo efficacy test.
- 48 and 49 are graphs showing the change in the amount of water intake of type 2 diabetic mice in the in-vivo efficacy test.
- 50 to 52 show the results of the in silico immunogenicity test in MHC Class I.
- 53 to 55 show the results of the in silico immunogenicity test in MHC Class II.
- prevention refers to any action that suppresses or delays the onset of a disease by administration of the composition
- treatment means that the symptoms of the suspected disease and onset individual are improved or beneficially changed by administration of the composition means any action.
- the term "subject” is a mammal, preferably a human, but includes companion animals (eg, dogs, cats, etc.), livestock (eg, cattle, sheep, pigs, horses, etc.) and laboratory animals (for example, rats, mice, guinea pigs, etc.).
- companion animals eg, dogs, cats, etc.
- livestock eg, cattle, sheep, pigs, horses, etc.
- laboratory animals for example, rats, mice, guinea pigs, etc.
- the pharmaceutical composition of the present invention may be administered parenterally or orally according to a desired method, and the dosage may vary depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, etc. Its scope is diverse.
- the therapeutically effective amount of the composition may vary depending on the administration method, the target site, and the condition of the patient.
- GCG may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 1, wild-type glucagon (Native GCG).
- GCG analog means that some amino acids of wild-type glucagon protein are substituted.
- it may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 2 or 3. More preferably, amino acids 16 to 20 from the N-terminus of the wild-type glucagon protein are substituted in SRRAQ by ERRAK, amino acids 23 to 24 are substituted in VQ by IE, and amino acids 27 to 29 are substituted in MNT It may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 2, substituted with LSA.
- GLP-1 may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 4, wild-type GLP-1 (Native GLP-1).
- GLP-1 analog refers to a substitution of some amino acids in the wild-type GLP-1 protein.
- it may mean selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 5 to 14. More preferably, from the N-terminus of the wild-type GLP-1 protein, amino acid 2 is substituted from A to G, amino acid 16 is substituted from G to E, and amino acid 30 is substituted from R to GG, SEQ ID NO: It may mean a protein consisting of an amino acid sequence of 12.
- FGF21 may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 17, wild-type FGF21 (Native FGF21).
- FGF21 analog means that some amino acids of the wild-type FGF21 protein are substituted.
- it may mean selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 18 to 21. More preferably, from the N-terminus of the wild-type FGF21 protein, amino acids 19 are substituted from R to V, amino acids 98 to 100 are substituted from LLL to DLK, and amino acids 167 to 170 are substituted from SMVG to RLVE and amino acid 174 is substituted from G to L, and amino acids 179 to 181 are substituted with FE in YAS, and may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 20.
- GIP may refer to a wild-type GIP (Native GIP), which is a protein consisting of the amino acid sequence of SEQ ID NO: 22.
- GIP analog refers to a substitution of some amino acids of the wild-type GIP protein.
- it may mean selected from the group consisting of proteins consisting of the amino acid sequence of SEQ ID NOs: 23 to 26. More preferably, it may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 24, in which amino acid 2 is substituted from A to S from the N-terminus of the wild-type GIP protein.
- IL-1RA may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 27, wild-type IL-1RA (Native IL-1RA).
- IL-1RA analog means that some amino acids of the wild-type IL-1RA protein are substituted. Preferably, it may refer to a protein consisting of the amino acid sequence of SEQ ID NO: 28.
- the receptor protein prepared in the following Examples is a polypeptide represented by the following formula.
- X is a GCG analog consisting of the amino acid sequence of SEQ ID NO: 2
- Y is a GLP-1 analog consisting of the amino acid sequence of SEQ ID NO: 12
- Z is an FGF21 analog consisting of the amino acid sequence of SEQ ID NO: 20
- Ub (A) is a receptor ubiquitin consisting of the amino acid sequence of SEQ ID NO: 30,
- L is a linker consisting of the amino acid sequence of SEQ ID NO: 29,
- A is albumin consisting of the amino acid sequence of SEQ ID NO: 32.
- SEQ ID NOs of the amino acid sequences of each protein and signal peptide constituting the receptor protein are shown in Table 1.
- the donor protein prepared in Examples below is a polypeptide represented by the following formula.
- W is a GIP analog consisting of the amino acid sequence of SEQ ID NO: 24 or IL-1RA consisting of the amino acid sequence of SEQ ID NO: 27,
- L is a linker consisting of the sequence of SEQ ID NO: 29,
- Ub(D) is a donor ubiquitin consisting of the sequence of SEQ ID NO:31.
- SEQ ID NOs of each protein amino acid sequence constituting the donor protein are shown in Table 2.
- Donor-191 and D-191 refer to a donor protein comprising a GIP analog.
- Donor-192 and D-192 refer to a donor protein comprising IL-1RA.
- RD-191 and C-191 refer to a protein conjugate in which an acceptor protein and a donor protein including a GIP analog are bound.
- RD-192 and C-192 refer to a protein conjugate in which an acceptor protein and a donor protein including IL-1RA are bound.
- the receptor gene sequence which is a gene encoding the receptor protein
- it was cloned into pcDNA3.1(+), an expression vector having a simple structure having a CMV promoter and an ampicillin resistance gene.
- the PCR reaction was performed using Phusion High-Fidelity DNA polymerase (Thermo Fisher, Cat. No.: F530), first denaturation at 98 °C for 3 minutes, secondary denaturation at 98 °C for 10 seconds, primer conjugation at 60 °C for 30 seconds, elongation reaction 72 After repeating 18 times from the secondary denaturation to the elongation reaction during the course of 3 minutes at °C, the final elongation reaction was performed at 72 °C for 5 minutes.
- Phusion High-Fidelity DNA polymerase Thermo Fisher, Cat. No.: F530
- first denaturation at 98 °C for 3 minutes
- secondary denaturation at 98 °C for 10 seconds
- primer conjugation at 60 °C for 30 seconds
- elongation reaction 72 After repeating 18 times from the secondary denaturation to the elongation reaction during the course of 3 minutes at °C, the final elongation reaction was performed at 72 °C for 5 minutes.
- PCR reaction After the PCR reaction is finished, check whether the target gene is amplified through agarose gel electrophoresis, and then put the vector PCR product and the insult PCR product into a PCR tube by 10 ⁇ L one-to-one, and then add 0.5 ⁇ L of DpnI. gave. The tube was treated at 37°C for 1 hour to remove the template DNA and ligated. The ligated PCR product was transformed into DH5 ⁇ competent cells by heat shock treatment at 42 ° C. for 1 minute, plated on LB solid medium containing ampicillin, and then at 37 ° C. Colonies were obtained by stationary culture for 16 hours or more.
- the vector whose gene sequence has been confirmed is transformed into a DH5 ⁇ competent cell by heat shock treatment at 42 ° C for 1 minute, plated on LB solid medium containing ampicillin, and then at 37 ° C. Colonies were obtained by stationary culture for 16 hours or more. After taking a single colony and inoculating it in 5 mL of LB medium, it was incubated at 37 °C and 220 rpm for 16 hours. A part of this culture medium was again inoculated into 200 mL of LB medium containing ampicillin, and then incubated at 37 °C and 220 rpm for 16 hours. After the culture medium was centrifuged at 3500 rpm for 30 minutes to secure E.
- coli wet cells P1, P2, and P3 solutions of the DNA extraction kit (QIAGEN, Cat. No.: 12263) were added to break the cell wall, and proteins and DNA were separated A turbid DNA solution was obtained.
- a plasmid DNA pellet was obtained from the DNA suspension obtained using the purification column of the DNA extraction kit (QIAGEN, Cat. No.: 12263). The pellet was dissolved in cell culture water (Sigma Aldrich, W3500) and filtered through a 0.22 ⁇ m filter. The extracted plasmid DNA was used for protein expression after measuring the DNA concentration and purity using a nanodrop device (IMPLEN, Nanodrop NP-80).
- ExpiCHO-S Gibco, Cat. No.: A29127, Lot: 1974423 cells were inoculated at 4x10 6 cells/mL and prepared in an incubator at 37 °C, 80% humidity or more, 8% CO 2 It was mounted on an orbital shaker and cultured at 95 rpm (50 mm shaking diameter) conditions. After 24 hours, the cells were filtered through a 40 ⁇ m nylon filter (BD Falcon, Cat. No.: 352340) to remove clumps, and then cell viability and cell number were measured. The filtered cells were diluted with ExpiCHO-S expression medium (ExpiCHO Expression Media, Gibco, Cat. No.: A29100-01) to a final 6x10 6 cells/mL, and the final 200 mL of cells was placed in a 1 L flask. .
- ExpiCHO-S expression medium ExpiCHO Expression Media, Gibco, Cat. No.: A29100-01
- the receptor protein culture solution expressed in Example 2 was equilibrated with Equilibrium buffer (20 mM sodium phosphate, pH 7.0) onto Blue sepharose HP resin (GE, Cat. No.: 17-0413-01) column loading (loading) did. Impurities were removed through pre-elution (20 mM sodium phosphate, pH 7.0, 0.15 M KCl), and the receptor protein was recovered using an elution buffer (20 mM sodium phosphate, pH 7.0, 0.6 M KCl). The recovered receptor protein was subjected to dialysis with 20 mM sodium phosphate, pH 7.0 buffer to remove salt, and ultrafiltration was performed so that the final sample was 5 mg/mL. The results of receptor protein purification through SDS-PAGE are shown in FIG. 1 .
- the plasmid into which the donor gene was inserted was placed in BL21(DE3) competent cells and subjected to heat shock at 42 °C for 1 minute ( After transforming by heat shock) and plated on LB solid medium containing ampicillin, colonies were obtained by stationary culture at 37 ° C. for 16 hours or more. After taking a single colony and inoculating it in 50 mL of LB medium, seed culture was performed at 37 °C and 220 rpm for 16 hours.
- the main culture is performed by inoculating the seed culture medium in 1L LB medium containing ampicillin at a ratio of 1:100. did. After 2 hours of incubation at 37 °C and 220 rpm, when the OD reached 0.6 at 600 nm, 0.25 M IPTG was added and incubated at 16 °C and 220 rpm for 20 hours. After completion of the culture, E. coli wet cells were obtained by centrifugation at 3500 rpm for 30 minutes.
- the seed culture medium is inoculated into 1L LB medium containing ampicillin at a ratio of 1:100 to main culture was performed. Autoinduction was performed at 37 °C and 220 rpm for 24 hours. After completion of the culture, E. coli wet cells were obtained by centrifugation at 3500 rpm for 30 minutes.
- the cultured donor protein was purified by the following method, and the purification process is shown in FIG. 2 .
- Lysate was loaded on Ni-sepharose resin (QIAGEN, Cat. No.: 30250). After loading the sample, the non-specific protein was sufficiently washed and removed using a binding buffer (20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, 0.02 M imidazole). Thereafter, the Hig-SUMO-tagged donor protein was recovered using an elution buffer (20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, 0.25 M imidazole). The recovered His-SUMO-tagged donor protein was subjected to dialysis with 20 mM sodium phosphate, pH 7.0 buffer to remove salt and imidazole. The results of confirming the purification of the donor protein through the Ni column by SDS-PAGE are shown in FIGS. 3 and 4 .
- His-SUMO-tagged donor protein and SENP1 were subjected to SENP1 enzyme digestion at a ratio of 100 mg: 1 mg.
- the concentration of the protein recovered by Ni-purification was quantified, and SNEP1 (in-house) corresponding to 1/100 w/w of the amount (mg) of the His-SUMO tag attached donor protein was mixed.
- the reaction mixture was left at room temperature (15 to 25 °C) for 1 hour.
- the reaction mixture was loaded onto Ni-sepharose resin (QIAGEN, Cat. No.: 30250) equilibrated with Equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, 0.02 M imidazole).
- Equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, 0.02 M imidazole).
- Sample loading was performed, and the His-SUMO tag truncated donor protein was allowed to flow through.
- the remaining donor protein was recovered using an equilibrium buffer (20 mM sodium phosphate, pH 7.0, 0.5 M NaCl, 0.02 M imidazole), and the recovered donor protein was dialyzed with 20 mM sodium phosphate, pH 7.0 buffer. to remove salt and imidazole.
- the final donor product was subjected to ultrafiltration to 10 mg/mL. The results of confirming His-SUMO removal purification by SDS-PAGE are shown in FIGS. 5 and 6 .
- the donor recovered in the previous step was loaded onto a Capto Q ImpRes (GE, Cat. No.: 17-5470-15) column equilibrated with Equilibrium buffer (20 mM sodium phosphate, pH 7.0 buffer). The donor protein was allowed to flow through. The recovered proteins were concentrated to a high concentration. The results of polishing and purification of the donor protein are shown in FIGS. 7 and 8 .
- conjugation was performed using the acceptor protein produced in Example 3 and the donor protein produced in Example 5 .
- a mixture of the conditions shown in Table 3 was prepared, and a conjugation reaction was performed at 30° C. for 4 hours.
- the degree of conjugation was confirmed by loading 10 ⁇ g of the receptor on 8% SDS-PAGE for the reaction. The results are shown in FIGS. 10 and 11 .
- the reaction material is loaded onto Ni-sepharose resin (QIAGEN, Cat. No.: 30250) equilibrated with an equilibrium buffer (20 mM sodium phosphate, pH 8.0, 0.15 M NaCl), and then the sample is loaded. Impurities were removed using an equilibrium buffer (20 mM sodium phosphate, pH 8.0, 0.5 M NaCl). Thereafter, the conjugate was recovered using an elution buffer (25 mM Tris, pH 8.0, 0.15 M NaCl, 0.01 M imidazole). The recovered protein conjugates (C-191 and C-192) were subjected to dialysis with 20 mM sodium phosphate, pH 7.0 buffer to remove salt and imidazole. The results of Ni purification were confirmed through chromatography and shown in FIG. 12 .
- the conjugate recovered in the previous step was loaded onto a Capto Q ImpRes (GE, Cat. No.: 17-5470-15) column equilibrated with Equilibrium buffer (25 mM sodium phosphate, pH 7.0 buffer). Elution buffer (25 mM sodium phosphate, pH 7.0, 158 mM NaCl buffer) was used to recover the conjugate.
- the recovered protein conjugate was subjected to dialysis with 20 mM sodium phosphate, pH 7.0 buffer to remove salt and imidazole.
- the final conjugate product was subjected to ultrafiltration to a concentration of 5 mg/mL. The results are shown in FIGS. 13 and 14 .
- the protein conjugate recovered from AEX was dialyzed with a formulation buffer (4.6 mM Histidine, 5.7 mM Tris, pH 7.5, 10 mM Arginine, 0.1 g/mL trehalose) to remove salts and imidazole.
- the final conjugate product was subjected to ultrafiltration to a concentration of 5 mg/mL. The results are shown in FIG. 15 .
- GLP in the protein conjugates C-191 and C-192 which are GCG/GLP-1/FGF21/GIP or GCG/GLP-1/FGF21/IL-1RA receptor tetra agonist/antagonists prepared in Examples 1 to 9
- GLP-1 receptor, GIP receptor, and GCG receptor were respectively transient or transient using Cisbio cAMP Gs Dynamic kit #62AM4PEC.
- cAMP accumulation analysis in the stable overexpressed cell line was performed as follows.
- HEK293 cells were incubated for 2 to 3 days in an incubator at 37° C. 5% CO 2 so that the concentration of HEK293 cells was 70 to 80%. After removing the medium, treating with 2 mL of TryPLE Express, and incubating for 3 to 5 minutes in an incubator at 37° C. 5% CO 2 , the cells were dropped.
- the culture medium (MEM, 10% FBS, 1% Anti-anti) was diluted by adding 6 mL, transferred to a 15 mL tube, and centrifuged at 1000 rpm for 3 minutes. The supernatant was discarded and dissolved in 5 mL of medium. The number of cells was counted and the concentration was 3 X 10 5 cells/mL.
- the fluorescence of the sample in the plate was measured with a Synergy Neo2 instrument (Excitation wavelength: 330 nm, Emission wavelength: 665 nm and 620 nm).
- the HTRF ratio was calculated as follows.
- EC50 values were obtained using HTRF ratio plot values using GraphPad Prism 8 (curve-fitting of the log(agonist) vs. normalized response - variable slope equation).
- GLP-1R GLP-1 receptor
- GIPR GIP receptor
- GCG receptor GCGR
- C-191 had activity against each of the GLP-1 receptor, GIP receptor, and GCG receptor.
- C-192 also has activity against each of the GLP-1 receptor and the GCG receptor.
- FGF21 in the protein conjugates C-191 and C-192 which are GCG/GLP-1/FGF21/GIP or GCG/GLP-1/FGF21/IL-1RA receptor tetra agonists/antagonists prepared in Examples 1 to 9
- the PathHunter Detection Kit (Discover X, Cat. No. 93-) in a cell line overexpressing FGFR1/KLB (Discover X, Cat. No. 93-118C3) 0001)
- FGFR1/KLB function analysis was performed as follows.
- Cells were cultured to 70-80% full in T-75 flasks. The medium was removed and washed with 5 mL of pre-warmed PBS. After removing PBS, and adding 2 mL of AssayComplete cell detachment reagent, it was incubated for 3 minutes at 37°C 5% CO 2 in an incubator to drop the attached cells. It was mixed with 6 mL of AssayComplete cell plating 0 reagent, transferred to a 15 mL tube, centrifuged at 1,000 rpm for 3 minutes, and then released into 5 mL cell plating reagent. Cells were counted and brought to a concentration of 500,000 cells/mL.
- rhFGF21 (5X) and test sample (5X) prepared by 4-fold serial dilution were dispensed in duplicate by 10 ⁇ L, and incubated at room temperature for 4 hours.
- 10 ⁇ L of AssayComplete cell plating 0 reagent was added.
- 50 ⁇ L of AssayComplete cell plating 0 reagent was added.
- 30 ⁇ L of the detection reagent was dispensed, and after reacting for 1 hour at room temperature in a state in which light was blocked, luminescence was measured with a plate reader.
- the luminescence of the samples in the plate was measured with a Synergy Neo2 instrument.
- NF- ⁇ B reporter gene luminase assay reporter gene assay
- IL-1RA The ability of IL-1RA to inhibit NF- ⁇ B activity by IL-1 ⁇ among the GCG/GLP-1/FGF21/IL-1RA receptor quadruple (tetra) agonist/antagonist protein conjugate C-192 prepared in Examples 1 to 9
- luminase assays were performed on the NF- ⁇ B reporter (Luc) cell line (BPS Bioscience, Cat. No. 60650) as follows.
- Cells were cultured in a T-75 flask to 70-80% full. The medium was removed and washed once with 5 mL of pre-warmed PBS. Remove PBS, add 1 mL of TryPLE Express, and incubate in an incubator at 37 ° C. 5% CO 2 for 5 minutes to drop cells. Mixed with 4 mL Assay medium (10% FBS, 1% antibiotic in DMEM), transferred to a 15 mL tube, centrifuged at 1,000 rpm for 3 minutes, and then re-dissolved in 5 mL assay medium. Cells were counted and brought to a concentration of 500,000 cells/mL.
- Reference (10X) and sample (10X) prepared by 4-fold serial dilution were dispensed in duplicate by 5 ⁇ L. Then, 5 ⁇ L of 50 pM IL-1 ⁇ (10X) was dispensed, and incubated in a 5% CO 2 incubator for 4 hours. 50 ⁇ L of ONE-Glo reagent (Promega, Cat. No. E6120) was dispensed, respectively, and after incubation at room temperature for 5 minutes, luminescence was measured with a Synergy Neo2 instrument. At this time, before treatment with the ONE-Glo reagent, the plate was removed from the incubator for 15 minutes and allowed to reach room temperature.
- ONE-Glo reagent Promega, Cat. No. E6120
- IC50 values were obtained using GraphPad Prism 8 as shown below (curve-fitting of the log(antagonist) vs. normalized response - variable slope equation).
- the in vivo efficacy of the protein conjugate C-192 which is a GCG/GLP-1/FGF21/IL-1RA receptor quadruple (tetra) agonist/antagonist, prepared in Examples 1 to 9 against nonalcoholic steatohepatitis was verified by MCD (Methionine and Choline Deficient L-Amino Acid Diet) in C57BL/6J mice induced fatty liver.
- MCD Methionine and Choline Deficient L-Amino Acid Diet
- mice After inducing fatty liver by feeding MCD to male C57BL/6J mice for 8 weeks, the mice were divided into 6 groups shown in Table 7 below and drug administration was performed for 4 weeks.
- Table 7 As a comparative material, two types of currently commercially available liraglutide (Liraglutide, Saxenda) and duraglutide (Dulaglutide, Trulycity) were used.
- the administration composition was repeatedly administered subcutaneously using a disposable syringe according to each administration cycle. During the 8-week diet period, body weight was measured once a week, and group separation was performed significantly with the weight after 8 weeks.
- the normal control group was fed MCS (Methionine and Choline Sufficient L-Amino Acid Diet).
- ALT Alanine aminotransferase
- ALT indicates the degree of liver damage
- ALT/AST values are shown in Table 9 and FIG. 22 below.
- the ALT/AST value was found to be less than 1.0 in the group administered with liraglutide and duraglutide (comparative groups A and B), but the ALT/AST value in the group administered with C-192. It turned out that this exceeded 1.0.
- ALT/AST value is often less than 1 in liver disease, it can be seen that the degree of liver damage is reduced when the protein conjugate of the present invention is administered.
- FIG. 23 histopathological examination was observed through H&E and Masson's trichrome staining, and the results are shown in FIG. 23 .
- inflammation occurs in steatosis and lobules, and inflammatory cells can be identified during tissue staining.
- FIG. 23 it can be seen that in the group administered with the protein conjugate of 40 nmol/kg (experimental group B), compared with the negative control group, the fat and inflammatory cells were improved to the level of the normal control group.
- steatosis score based on the evaluation criteria shown in Table 10, steatosis score, lobular inflammation score, and NAS (NAFLD activity score) were evaluated.
- the group administered with the protein conjugate of the present invention all showed excellent results, and in particular, the group administered with the protein conjugate of 40 nmol/kg (Experimental Group B) was treated with liraglutide and duraglue. The evaluation results were significantly superior to those of the Tid-administered group.
- liver tissue was analyzed by ELISA for TGF- ⁇ , a marker of liver fibrosis, and the results are shown in Table 14 and FIG. 27 below.
- the TGF- ⁇ value was decreased in the group administered with the protein conjugate of the present invention, and in particular, the group administered with the protein conjugate of 40 nmol/kg (Experimental Group B) had a value almost similar to that of the normal control group. indicated.
- triglyceride accumulation in liver tissue was analyzed using the Triglyceride Assay Kit, and the results are shown in Table 15 and FIG. 28 below.
- the amount of triglyceride in the liver tissue was hardly decreased in the liraglutide and duraglutide administration group, but the protein conjugate administration group of the present invention showed almost similar values to the normal control group.
- ALT Alanine aminotransferase
- the ALT value did not decrease in the group administered with duraglutide, but it was confirmed that the ALT value significantly decreased in the group administered with C-191.
- ALT indicates the degree of liver damage
- AST/ALT values are shown in Table 18 and FIG. 30 below.
- ALT/AST value is often less than 1 in liver disease, it can be seen that the degree of liver damage is reduced when the protein conjugate of the present invention is administered.
- FIG. 31 histopathological examination was observed through H&E and Masson's trichrome staining, and the results are shown in FIG. 31 .
- inflammation occurs in steatosis and lobules, and inflammatory cells can be identified during tissue staining.
- FIG. 31 it can be seen that the group administered with 10 nmol/kg of the protein conjugate showed improvements in fat and inflammatory cells to that of the normal control group, compared to the negative control group.
- steatosis score based on the evaluation criteria shown in Table 10, steatosis score, lobular inflammation score, and NAS (NAFLD activity score) were evaluated.
- the group administered with the protein conjugate of the present invention all showed excellent results, and showed significantly superior evaluation results than the group administered with duraglutide.
- liver tissue was analyzed by ELISA for TGF- ⁇ , a marker of liver fibrosis, and the results are shown in Table 22 and FIG. 35 below.
- triglyceride accumulation in liver tissue was analyzed using the Triglyceride Assay Kit, and the results are shown in Table 23 and FIG. 36 below. Although the amount of triglyceride in the liver tissue was hardly decreased in the duraglutide administration group, the protein conjugate administration group of the present invention showed a value almost similar to that of the normal control group.
- the protein conjugate C-191 administration group of the present invention exhibits a significantly superior effect in all experiments compared to the duraglutide administration group.
- No group Average weight (g) diet dosing composition Dosage dosing cycle number of doses One normal control 27.1 ⁇ 1.3 for laboratory animals solid feed excipient - 1 time / 2 days Episode 28 2 negative control 44.7 ⁇ 2.3 RD western diet excipient - 1 time / 2 days Episode 28 3 Experimental group A 43.9 ⁇ 1.1 RD western diet C-192 10 nmol/kg 1 time / 2 days Episode 28 4 Experimental group B 42.1 ⁇ RD western diet C-192 30 nmol/kg 1 time / 2 days Episode 28 5 Experimental group C 41.7 ⁇ 4.4 RD western diet C-192 60 nmol/kg 1 time / 2 days Episode 28
- excipients were administered to the normal control group and the negative control group, and C-192 was administered at 10, 30 and 60 nmol/kg doses for the experimental group.
- general symptoms such as appearance, behavior and excretion were observed once a day.
- blood was collected from the abdominal vena cava, put blood in an SST tube, and centrifuged at 3,000 rpm for 15 minutes to separate serum. Markers were measured.
- Lipid-related biomarkers unit How to measure triglycerides (triglycerides, TG) mg/dL GPO-HMMPS Glycerol blanking free fatty acids (Non esterified fatty acid, NEFA) ⁇ Eq/L ACS/ACOD total cholesterol (total cholesterol, T-Chol) mg/dL Cholesterol oxidase-HMMPS low-density lipoprotein cholesterol (LDL-Cholesterol) mg/dL Selective protection enzymatic high-density lipoprotein cholesterol (HDL-Cholesterol) mg/dL Direct
- TG serum triglyceride
- NEFA free fatty acid
- T-Chol total cholesterol
- LDL low-density lipoprotein cholesterol
- HDL high-density lipoprotein cholesterol
- a type 2 diabetes model mouse Evaluation was performed using db/db mice.
- the db/db mouse is an animal model in which obesity and type 2 diabetes occur because mutations in Lepr, a leptin receptor gene on chromosome 4, do not result in signal transduction of leptin, a hormone secreted by adipocytes.
- C57BL/6J mice were used as normal animals, and 8-week-old mice purchased 7-week-old male from Japan SLC and quarantined and acclimatized for 7 days were used as experimental animals.
- the composition of the experimental group was classified into a normal control group, a negative control group, a test substance administration group, and a positive control group. After quarantine and acclimatization, 5 animals per group were separated so that body weight and blood sugar were equal. The administration route was administered subcutaneously in the same manner as the clinical application route, and the administration was conducted for 8 days. For the frequency of administration, the normal control, negative control and experimental groups were administered once/day, and the positive control group was administered once/two days.
- the administration composition was administered as an excipient for the normal control group and the negative control group, and C-192 was administered at 10 and 60 nmol/kg doses for the experimental group.
- C-192 was administered at 10 and 60 nmol/kg doses for the experimental group.
- general symptoms were observed once/day, and blood glucose, body weight, feed and negative water were measured to confirm the anti-diabetic effect in db/db mice.
- Blood glucose was measured by non-fasting blood glucose, and blood was collected from the tail vein once/2 days before administration and measured using a blood glucose meter (G-Doctor). Measurements were carried out on the 1st day of administration, 4th day of administration, and 8th day of administration in order to confirm changes in body weight, feed, and negative water, and the results are shown in Table 28 and FIGS. 42 to 49 below.
- Immunogenicity refers to a property that induces an immune response when a drug is administered into the human body, and is a factor that affects not only drug efficacy but also safety.
- silico analysis using an immunogenicity-inducing sequence database and computer analysis program and in vitro immunogenicity evaluation using human-derived PBMCs were performed.
- HLA type turn HLA type turn HLA type
- the protein sequences of each acceptor and donor were predicted to have a low probability of binding to the antigen-binding sites of MHC I and MHC II for each of the 27 HLA types. It was predicted that safety was high as each acceptor and donor had low immunogenicity.
- the EC50 values of the GLP-1 receptor single agonists were calculated and shown in Table 30 below.
- the EC50 values of the GLP-1/GIP receptor dual agonists were calculated and shown in Table 32 below.
- NF- ⁇ B reporter gene luminase analysis was performed in the same manner as in Test Example 3. .
- IC50 values of the IL-1RA receptor single antagonists were calculated and shown in Table 37 below.
- the protein conjugate of the present invention has excellent effects in the prevention and treatment of nonalcoholic steatohepatitis (NASH), fatty liver, liver fibrosis, cirrhosis, liver cancer, obesity or diabetes, and has excellent stability.
- NASH nonalcoholic steatohepatitis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
단백질 | 아미노산 서열 |
GCG 아날로그 | 서열번호 2 |
GLP-1 아날로그 | 서열번호 12 |
FGF21 아날로그 | 서열번호 20 |
Linker | 서열번호 29 |
Ub(A) | 서열번호 30 |
Albumin | 서열번호 32 |
HSA | 서열번호 33 |
IgGκ | 서열번호 34 |
단백질 | 아미노산 서열 |
GIP | 서열번호 24 |
IL-1RA | 서열번호 27 |
Linker | 서열번호 29 |
Ub(D) | 서열번호 31 |
수용체 | 공여체 | ATP | mUBA1 | UBC13
/MMS2 |
Buffer | Reducing agent | Vol. | |
조건 | 10 μM | 15 μM | 4 mM | 1 μM | 10 μM | 50mM Tris pH7.6,2.5mM MgCl2 | 0.05 mM TCEP | 100 mL |
EC50
(pM) |
GLP-1R | GIPR | GCGR | |||||||||
1 | 2 | Mean | SD | 1 | 2 | Mean | SD | 1 | 2 | Mean | SD | |
Liraglutide | 40.7 | 36.7 | 38.7 | 2.83 | - | - | - | - | - | - | - | - |
Dulaglutide | 1.23 | 0.9 | 1.07 | 0.23 | - | - | - | - | - | - | - | - |
GIP(1-39) | - | - | - | - | 15.4 | 14.1 | 14.8 | 0.92 | - | - | - | - |
GCG | - | - | - | - | - | - | - | - | 39.3 | 30.4 | 34.9 | 6.29 |
C-191 | 25.4 | 36.5 | 31.0 | 7.85 | 110 | 85 | 97.5 | 17.7 | 4487 | 3832 | 4160 | 463 |
C-192 | 13.2 | 15.9 | 14.6 | 1.91 | - | - | - | - | 286 | 251 | 269 | 24.7 |
EC50 (nM) | rhFGF21 | C-191 | C-192 |
1 | 0.75 | 92.2 | 42.2 |
2 | 0.88 | 45.1 | 40.5 |
Mean | 0.82 | 68.7 | 41.4 |
SD | 0.09 | 33.3 | 1.20 |
IC50 (pM) | rhIL-1RA | C-192 |
1 | 39.9 | 561 |
2 | 51.5 | 594 |
3 | 46.6 | 708 |
4 | 51.9 | 568 |
Mean | 47.5 | 607 |
SD | 4.85 | 68.4 |
No | 그룹 | 식이 | 투여 조성물 | 투여 용량 | 투여 주기 | 투여 횟수 |
1 | 정상 대조군 | MCS | - | - | - | - |
2 | 음성 대조군 | MCD | 부형제 | - | - | - |
3 | 실험군 A | MCD | C-192 | 5 nmol/kg | 1회/2일 | 14회 |
4 | 실험군 B | MCD | C-192 | 40 nmol/kg | 1회/2일 | 14회 |
5 | 비교군 A | MCD | Liraglutide | 50 nmol/kg | 2회/1일 | 56회 |
6 | 비교군 B | MCD | Dulaglutide | 2 nmol/kg | 1회/2일 | 14회 |
No | 그룹 | ALT |
1 | 정상 대조군 | 18.3 |
2 | 음성 대조군 | 230.6 |
3 | 실험군 A | 178.3 |
4 | 실험군 B | 126.3 |
5 | 비교군 A (리라글루티드 투여군) | 223.0 |
6 | 비교군 B (두라글루티드 투여군) | 220.5 |
No | 그룹 | ALT/AST 값 |
1 | 정상 대조군 | 1.77 |
2 | 음성 대조군 | 0.98 |
3 | 실험군 A | 1.35 |
4 | 실험군 B | 1.53 |
5 | 비교군 A (리라글루티드 투여군) | 0.99 |
6 | 비교군 B (두라글루티드 투여군) | 0.79 |
ITEM | Definition | Score |
Steatosis | Low to medium power evaluation of parenchymal involvement by steatosis | |
<5% | 0 | |
5~33% | 1 | |
>33~66% | 2 | |
>66% | 3 | |
Lobular inflammation | Overall assessment of all inflammatory foci | |
No foci | 0 | |
<2 foci per 200Υfield | 1 | |
2~4 foci per 200Υfield | 2 | |
>4 foci per 200Υfield | 3 | |
Ballooning | None | 0 |
Few balloon cells | 1 | |
Many cells/prominet ballooning | 2 |
No | 그룹 | 지방증 점수 (Steatosis) |
1 | 정상 대조군 | 0 |
2 | 음성 대조군 | 2.1 |
3 | 실험군 A | 1.7 |
4 | 실험군 B | 0.9 |
5 | 비교군 A (리라글루티드 투여군) | 1.6 |
6 | 비교군 B (두라글루티드 투여군) | 1.9 |
No | 그룹 | 소엽 염증 점수
(Lobular inflammation) |
1 | 정상 대조군 | 0.3 |
2 | 음성 대조군 | 1.3 |
3 | 실험군 A | 1.2 |
4 | 실험군 B | 0.2 |
5 | 비교군 A (리라글루티드 투여군) | 0.5 |
6 | 비교군 B (두라글루티드 투여군) | 1.5 |
No | 그룹 | NAS (NAFLD Activity Score) |
1 | 정상 대조군 | 0.3 |
2 | 음성 대조군 | 3.4 |
3 | 실험군 A | 2.9 |
4 | 실험군 B | 1.2 |
5 | 비교군 A (리라글루티드 투여군) | 2.2 |
6 | 비교군 B (두라글루티드 투여군) | 3.4 |
No | 그룹 | Hepatic TGF-β |
1 | 정상 대조군 | 74.40 |
2 | 음성 대조군 | 164.10 |
3 | 실험군 A | 135.50 |
4 | 실험군 B | 98.70 |
5 | 비교군 A (리라글루티드 투여군) | 136.40 |
6 | 비교군 B (두라글루티드 투여군) | 159.60 |
No | 그룹 | Hepatic Triglyceride |
1 | 정상 대조군 | 17.76 |
2 | 음성 대조군 | 40.31 |
3 | 실험군 A | 25.69 |
4 | 실험군 B | 24.43 |
5 | 비교군 A (리라글루티드 투여군) | 40.69 |
6 | 비교군 B (두라글루티드 투여군) | 40.78 |
No | 그룹 | 식이 | 투여 조성물 | 투여 용량 | 투여 주기 | 투여 횟수 |
1 | 정상 대조군 | MCS | - | - | - | - |
2 | 음성 대조군 | MCD | 부형제 | - | - | - |
3 | 실험군 A | MCD | C-191 | 10 nmol/kg | 1회/2일 | 14회 |
4 | 비교군 B | MCD | Dulaglutide | 2 nmol/kg | 1회/2일 | 14회 |
No | 그룹 | ALT |
1 | 정상 대조군 | 19.1 |
2 | 음성 대조군 | 312.4 |
3 | 실험군 A | 151.9 |
4 | 비교군 A (두라글루티드 투여군) | 246.8 |
No | 그룹 | AST/ALT 값 |
1 | 정상 대조군 | 1.84 |
2 | 음성 조군 | 0.82 |
3 | 실험군 A | 0.98 |
4 | 비교군 A (두라글루티드 투여군) | 0.76 |
No | 그룹 | 지방증 점수 (Steatosis) |
1 | 정상 대조군 | 0 |
2 | 음성 대조군 | 2.4 |
3 | 실험군 A | 1.4 |
4 | 비교군 A (두라글루티드 투여군) | 1.8 |
No | 그룹 | 소엽 염증 점수
(Lobular inflammation) |
1 | 정상 대조군 | 0.2 |
2 | 음성 대조군 | 1.6 |
3 | 실험군 A | 1.0 |
4 | 비교군 A (두라글루티드 투여군) | 1.6 |
No | 그룹 | NAS (NAFLD Activity Score) |
1 | 정상 대조군 | 0.2 |
2 | 음성 대조군 | 4.0 |
3 | 실험군 A | 2.4 |
6 | 비교군 A (두라글루티드 투여군) | 3.4 |
No | 그룹 | Hepatic TGF-β |
1 | 정상 대조군 | 77.3 |
2 | 음성 대조군 | 177.9 |
3 | 실험군 A | 117.4 |
4 | 비교군 A (두라글루티드 투여군) | 165.3 |
No | 그룹 | Hepatic Triglyceride |
1 | 정상 대조군 | 17.13 |
2 | 음성 대조군 | 40.09 |
3 | 실험군 A | 24.02 |
6 | 비교군 A (두라글루티드 투여군) | 36.08 |
No | 그룹 | 평균체중(g) | 식이 | 투여 조성물 | 투여 용량 | 투여 주기 | 투여 횟수 |
1 | 정상 대조군 | 27.1 ± 1.3 | 실험동물용
고형사료 |
부형제 | - | 1회/2일 | 28회 |
2 | 음성 대조군 | 44.7 ± 2.3 | RD western diet | 부형제 | - | 1회/2일 | 28회 |
3 | 실험군 A | 43.9 ± 1.1 | RD western diet | C-192 | 10 nmol/kg | 1회/2일 | 28회 |
4 | 실험군 B | 42.1 ± 4.1 | RD western diet | C-192 | 30 nmol/kg | 1회/2일 | 28회 |
5 | 실험군 C | 41.7 ± 4.4 | RD western diet | C-192 | 60 nmol/kg | 1회/2일 | 28회 |
지질 관련 바이오마커 | 단위 | 측정방법 |
중성지방
(triglycerides, TG) |
mg/dL | GPO-HMMPS Glycerol blanking |
유리지방산
(Non esterified fatty acid, NEFA) |
μEq/L | ACS·ACOD |
총콜레스테롤
(total cholesterol, T-Chol) |
mg/dL | Cholesterol oxidase-HMMPS |
저밀도 지단백 콜레스테롤
(LDL-Cholesterol) |
mg/dL | Selective protection enzymatic |
고밀도 지단백 콜레스테롤
(HDL-Cholesterol) |
mg/dL | Direct |
No | 그룹 | TG
(mg/dL) |
NEFA
(μEq/L) |
T-Chol
(mg/dL) |
LDL
(mg/dL) |
HDL
(mg/dL) |
1 | 정상 대조군 | 14.7 | 1.2 | 105.3 | 2.9 | 62.8 |
2 | 음성 대조군 | 26.0 | 1.5 | 241.8 | 21.7 | 99.2 |
3 | 실험군 A | 24.2 | 1.3 | 227.0 | 19.9 | 102.8 |
4 | 실험군 B | 18.0 | 1.1 | 162.0 | 13.6 | 74.7 |
5 | 실험군 C | 16.0 | 1.2 | 167.2 | 12.7 | 79.8 |
No | 계통 및 종 | 그룹 | 투여 조성물 | 투여 용량 | 투여 주기 | 투여 횟수 |
1 | C57BL/6J mouse | 정상 대조군 | 부형제 | - | 1회/1일 | 8 회 |
2 | db/db mouse | 음성 대조군 | 부형제 | - | 1회/1일 | 8 회 |
3 | 실험군 A | C-192 | 10 nmol/kg | 1회/1일 | 8 회 | |
4 | 실험군 B | C-192 | 60 nmol/kg | 1회/1일 | 8 회 | |
5 | 양성 대조군 | Semaglutide | 10 nmol/kg | 1회/2일 | 4 회 |
No | 그룹 | Glucose
(mg/dL) |
Weight
(g) |
Food
(g) |
Water
(mL) |
1 | 정상 대조군 | 161.0 | 23.6 | 15.4 | 33.1 |
2 | 음성 대조군 | 561.9 | 33.2 | 26.6 | 97.2 |
3 | 실험군 A | 409.6 | 33.7 | 20.4 | 61.5 |
4 | 실험군 B | 216.8 | 30.6 | 16.7 | 48.6 |
5 | 양성 대조군 | 444.5 | 32.3 | 21.9 | 41.3 |
순번 | HLA type | 순번 | HLA type | |
1 | HLA-DRB1*01:01 | 15 | HLA-DRB5*01:01 | |
2 | HLA-DRB1*03:01 | 16 | HLA-DQA1*05:01/DQB1*02:01 | |
3 | HLA-DRB1*04:01 | 17 | HLA-DQA1*05:01/DQB1*03:01 | |
4 | HLA-DRB1*04:05 | 18 | HLA-DQA1*03:01/DQB1*03:02 | |
5 | HLA-DRB1*07:01 | 19 | HLA-DQA1*04:01/DQB1*04:02 | |
6 | HLA-DRB1*08:02 | 20 | HLA-DQA1*01:01/DQB1*05:01 | |
7 | HLA-DRB1*09:01 | 21 | HLA-DQA1*01:02/DQB1*06:02 | |
8 | HLA-DRB1*11:01 | 22 | HLA-DPA1*02:01/DPB1*01:01 | |
9 | HLA-DRB1*12:01 | 23 | HLA-DPA1*01:03/DPB1*02:01 | |
10 | HLA-DRB1*13:02 | 24 | HLA-DPA1*01/DPB1*04:01 | |
11 | HLA-DRB1*15:01 | 25 | HLA-DPA1*03:01/DPB1*04:02 | |
12 | HLA-DRB3*01:01 | 26 | HLA-DPA1*02:01/DPB1*05:01 | |
13 | HLA-DRB3*02:02 | 27 | HLA-DPA1*02:01/DPB1*14:01 | |
14 | HLA-DRB4*01:01 |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
Liraglutide | Transient | 43.0 ± 10.6 | n=11 | - |
Stable | 50.3 ± 21.9 | n=8 | ||
Dulaglutide | Stable | 1.45 ± 0.45 | n=6 | - |
GLP-1(7-36)_native | Transient | 4.00 | n=1 | 서열번호 4 |
GLP#1 | Transient | 159 | n=1 | 서열번호 5 |
GLP#3 | Transient | 2.25 ± 0.19 | n=2 | 서열번호 6 |
GLP#4 | Transient | 3.19 ± 0.74 | n=2 | 서열번호 7 |
GLP#5 | Transient | 7.52 | n=1 | 서열번호 8 |
GLP#6 | Transient | 1.50 ± 0.06 | n=2 | 서열번호 9 |
GLP#7 | Transient | 23.0 | n=1 | 서열번호 10 |
GLP#8 | Transient | 1.95 ± 0.03 | n=2 | 서열번호 11 |
GLP#9 | Transient | 0.71 ± 0.37 | n=3 | 서열번호 12 |
Stable | 2.08 ± 1.60 | n=4 | ||
GLP#10 | Transient | 8.26 ± 4.02 | n=2 | 서열번호 13 |
GLP#11 | Transient | 6.05 | n=1 | 서열번호 14 |
GLP#12 | Transient | 559 | n=1 | - |
GLP#13 | Transient | 31.9 ± 7.28 | n=2 | - |
GLP#14 | Transient | >5000 | n=1 | - |
GLP#15 | Transient | >5000 | n=1 | - |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
GCG#2 | Transient | 52.0 ± 27.4 | n=2 | 서열번호 2 |
Stable | 10.1 ± 1.23 | n=2 | ||
GCG#3 | Transient | 43.9 ± 28.3 | n=2 | 서열번호 3 |
Stable | 25.6 ± 26.9 | n=3 | ||
GLP/GCG#1 | Transient | 588 | n=1 | - |
GLP/GCG#2 | Transient | 201 | n=1 | - |
GLP/GCG#3 | Transient | 13 | n=1 | 서열번호 15 |
GLP/GCG#4 | Transient | 15.0 ± 7.00 | n=2 | - |
GLP/GCG#5 | Transient | 165 | n=1 | - |
GLP/GCG#6 | Transient | 129 | n=1 | - |
GLP/GCG#7 | Transient | 3860 | n=1 | - |
GLP/GCG#8 | Transient | 12.5 | n=1 | - |
GLP/GCG#9 | Transient | 1589 | n=1 | - |
GLP/GCG#10 | Transient | 9742 | n=1 | - |
GLP/GCG#11 | Transient | >5000 | n=1 | - |
GLP/GCG#12 | Transient | 80.1 | n=1 | - |
GLP/GCG#13 | Transient | 604 | n=1 | - |
GLP/GCG#14 | Transient | 221 | n=1 | - |
GLP/GCG#15 | Transient | 16 | n=1 | 서열번호 16 |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
GLP/GIP#2 | Transient | 57.8 | n=1 | - |
GLP/GIP#3 | Transient | >5000 | n=1 | - |
GLP/GIP#4 | Transient | >5000 | n=1 | - |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
GIP native-Ub | Transient | 8.93 ± 5.77 | n=4 | 서열번호 22 |
Stable | 35.0 | n=1 | ||
GIP#1 | Transient | 17.5 ± 10.6 | n=3 | 서열번호 23 |
GIP#2 | Transient | 6.63 ± 3.87 | n=3 | 서열번호 24 |
Stable | 12.0 ± 5.73 | n=2 | ||
GIP#3 | Transient | 171 | n=1 | - |
GIP#4 | Transient | >5000 | n=1 | - |
GIP#5 | Transient | 81.9 | n=1 | 서열번호 25 |
GIP#6 | Transient | 398 | n=1 | - |
GIP#7 | Transient | 76.9 | n=1 | 서열번호 26 |
GIP#8 | Transient | 560 | n=1 | - |
GLP/GIP#2 | Transient | 128 | n=1 | - |
GLP/GIP#3 | Transient | 566 | n=1 | - |
GLP/GIP#4 | Transient | 1283 | n=1 | - |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
GCG native-Ub | Transient | 41.7 ± 29.9 | n=3 | 서열번호 1 |
Stable | 35.3 ± 32.7 | n=2 | ||
GCG#1 | Transient | >5000 | n=1 | - |
GCG#2 | Transient | 41.7 ± 5.51 | n=3 | 서열번호 2 |
Stable | 68.5 ± 41.8 | n=2 | ||
GCG#3 | Transient | 47.8 ± 21.9 | n=3 | 서열번호 3 |
Stable | 21.1 ± 12.3 | n=3 | ||
GCG#4 | Transient | >5000 | n=1 | - |
GCG#5 | Transient | 661 ± 193 | n=3 | - |
GCG#6 | Transient | 8400 | n=1 | - |
GCG#7 | Transient | 956 | n=1 | - |
GCG#8 | Transient | 761 ± 73.5 | n=2 | - |
GCG#9 | Transient | 1073 | n=1 | - |
GCG#10 | Transient | >5000 | n=1 | - |
GCG#11 | Transient | >5000 | n=1 | - |
구분 | 세포주 | EC50 (pM) | Comments | 서열번호 |
GLP/GCG#1 | Transient | >5000 | n=1 | - |
GLP/GCG#2 | Transient | >5000 | n=1 | - |
GLP/GCG#3 | Transient | >5000 | n=1 | 서열번호 15 |
GLP/GCG#4 | Transient | >5000 | n=1 | - |
GLP/GCG#5 | Transient | >5000 | n=1 | - |
GLP/GCG#6 | Transient | >6250 | n=1 | - |
GLP/GCG#7 | Transient | >5000 | n=1 | - |
GLP/GCG#8 | Transient | >5000 | n=1 | - |
GLP/GCG#9 | Transient | >5000 | n=1 | - |
GLP/GCG#10 | Transient | >5000 | n=1 | - |
GLP/GCG#11 | Transient | >5000 | n=1 | - |
GLP/GCG#12 | Transient | 321 | n=1 | - |
GLP/GCG#13 | Transient | >5000 | n=1 | - |
GLP/GCG#14 | Transient | >5000 | n=1 | - |
GLP/GCG#15 | Transient | 424 | n=1 | 서열번호 16 |
구분 | EC50 (nM) | Comments | 서열번호 |
rhFGF21 (native) | 1.17 ± 0.56 | n=4 | 서열번호 17 |
FGF#1 | 21.0 ± 0.49 | n=2 | 서열번호 18 |
FGF#5 | 22.3 ± 0.71 | n=2 | 서열번호 19 |
FGF#7 | 17.7 ± 2.55 | n=2 | 서열번호 20 |
FGF#9 | 19.1 ± 0.49 | n=2 | 서열번호 21 |
FGF#11 | > 5000 | n=1 | - |
FGF#12 | > 5000 | n=1 | - |
FGF#13 | > 5000 | n=1 | - |
FGF#14 | > 5000 | n=1 | - |
FGF#15 | > 5000 | n=1 | - |
구분 | IC50 (pM) | Comments | 서열번호 |
rhIL-1RA (native) | 68.6 ± 7.71 | n=2 | 서열번호 27 |
IL-1RA-Ub(Donor) | 236 ± 43.8 | n=2 | 서열번호 28 |
Claims (26)
- 폴리유비퀴틴,상기 폴리유비퀴틴에 직접 결합되거나 링커에 의해 결합되는 캐리어 (carrier), 및상기 폴리유비퀴틴 또는 캐리어에 직접 결합되거나 링커에 의해 결합되는 생체분자를 포함하고,상기 폴리유비퀴틴은 (i) 유비퀴틴의 라이신이 아르기닌 또는 알라닌으로 치환될 수 있으나 치환되지 않은 하나 이상의 라이신을 포함하는 수용체 유비퀴틴, 및 (ii) 유비퀴틴의 모든 라이신이 아르기닌 또는 알라닌으로 치환된 공여체 유비퀴틴으로 이루어지며,상기 생체분자는 GCG, GLP-1, FGF21, GIP 및 IL-1RA; 이의 아날로그; GCG 및 GLP-1 이중 수용체 작용제; 및 GLP-1 및 GIP 이중 수용체 작용제로 구성된 군에서 2 이상 선택된 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 GCG 및 이의 아날로그는 서열번호 1 내지 3의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 선택된 것을 특징으로 하는 단백질 결합체.
- 제2항에 있어서, 상기 GCG 아날로그는 서열번호 2의 아미노산 서열로 이루어지는 단백질인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 GLP-1 및 이의 아날로그는 서열번호 4 내지 14의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 선택된 것을 특징으로 하는 단백질 결합체.
- 제4항에 있어서, 상기 GLP-1 아날로그는 서열번호 12의 아미노산 서열로 이루어지는 단백질인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 GCG 및 GLP-1 이중 수용체 작용제는 서열번호 15 및 16의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 선택된 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 FGF21 및 이의 아날로그는 서열번호 17 내지 21의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 선택된 것을 특징으로 하는 단백질 결합체.
- 제7항에 있어서, 상기 FGF21 아날로그는 서열번호 20의 아미노산 서열로 이루어지는 단백질인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 GIP 및 이의 아날로그는 서열번호 22 내지 26의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 하나 이상 선택된 것을 특징으로 하는 단백질 결합체.
- 제9항에 있어서, 상기 GIP 및 이의 아날로그는 서열번호 24의 아미노산 서열로 이루어지는 단백질인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 IL-1RA 및 이의 아날로그는 서열번호 27 및 28의 아미노산 서열로 이루어지는 단백질로 구성된 군에서 하나 이상 선택된 것을 특징으로 하는 단백질 결합체.
- 제11항에 있어서, 상기 IL-1RA는 서열번호 27의 아미노산 서열로 이루어지는 단백질인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 폴리유비퀴틴은 유비퀴틴의 N-말단에서 6, 11, 27, 29, 33, 및 48번 라이신이 아르기닌으로 치환된 수용체 유비퀴틴 및 유비퀴틴의 모든 라이신이 아르기닌으로 치환된 공여체 유비퀴틴으로 이루어진 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 폴리유비퀴틴은 서열번호 30의 아미노산 서열로 이루어지는 수용체 유비퀴틴 및 서열번호 31의 아미노산 서열로 이루어지는 공여체 유비퀴틴으로 이루어진 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 링커는 GGGGS, EAAAK 또는 VPPPPP가 1개 내지 30개 반복하여 조합된 아미노산 서열로 이루어지는 폴리펩타이드인 것을 특징으로 하는 단백질 결합체.
- 제15항에 있어서, 상기 링커는 서열번호 29의 아미노산 서열로 이루어지는 폴리펩타이드인 것을 특징으로 하는 단백질 결합체.
- 제1항에 있어서, 상기 캐리어는 알부민, 항체단편, scFc (single chain Fc), scFc 다이머 (single chain Fc-dimer), 트랜스페린 (transferrin), XTEN (genetic fusion of non-exact repeat peptide sequence), CTP (carboxy-terminal peptide), PAS (proline-alanine-serine polymer), ELK (elastin-like peptide), HAP (homo-amino acid polymer), GLK (gelatin-like protein), PEG (poly ethylene glycol), 및 지방산 (fatty acid)으로 구성된 군에서 선택된 것을 특징으로 하는 단백질 결합체.
- 제17항에 있어서, 상기 캐리어는 알부민인 것을 특징으로 하는 단백질 결합체.
- 하기 식으로 표현되는 단백질 결합체:상기 식에서,W, X, Y 및 Z는 각각 서열번호 2의 아미노산 서열로 이루어지는 GCG 아날로그, 서열번호 12의 아미노산 서열로 이루어지는 GLP-1 아날로그, 서열번호 20의 아미노산 서열로 이루어지는 FGF21 아날로그, 서열번호 24의 아미노산 서열로 이루어지는 GIP 아날로그, 및 서열번호 27의 아미노산 서열로 이루어지는 IL-1RA로 구성된 군에서 선택되는 생체분자이고,Ub(A)는 서열번호 30의 아미노산 서열로 이루어지는 수용체 유비퀴틴이고,Ub(D)는 서열번호 31의 아미노산 서열로 이루어지는 공여체 유비퀴틴이고,L은 각각 독립적으로 부재 또는 링커 (Linker)이고,A는 캐리어 (Carrier)이고,Ub(A) 및 Ub(D)는 공유결합으로 연결된다.
- 제19항에 있어서,X는 서열번호 2의 아미노산 서열로 이루어지는 GCG 아날로그이고, Y는 서열번호 12의 아미노산 서열로 이루어지는 GLP-1 아날로그이고, Z는 서열번호 20의 아미노산 서열로 이루어지는 FGF21 아날로그이고, W는 서열번호 24의 아미노산 서열로 이루어지는 GIP 아날로그 또는 서열번호 27의 서열로 이루어지는 IL-1RA인 것을 특징으로 하는, 단백질 결합체.
- 제19항에 있어서, 상기 링커는 서열번호 29의 아미노산 서열로 이루어지는 폴리펩타이드인 것을 특징으로 하는 단백질 결합체.
- 제19항에 있어서, 상기 캐리어는 알부민인 것을 특징으로 하는 단백질 결합체.
- 제1항 내지 제22항 중 어느 한 항의 단백질 결합체를 포함하는, 비알콜성 지방간염, 지방간, 간섬유화, 간경변, 간암, 비만 또는 당뇨 질환의 예방 또는 치료용 약학 조성물.
- 제23항의 조성물을 인간을 제외한 개체에게 투여하는 단계를 포함하는, 비알콜성 지방간염, 지방간, 간섬유화, 간경변, 간암, 비만 또는 당뇨 질환의 예방 또는 치료 방법.
- (i) 하기 식으로 표현되는 수용체 단백질을 제조하는 단계;X-L-Y-L-Ub(A)-L-A-L-Z(ii) 하기 식으로 표현되는 공여체 단백질을 제조하는 단계; 및W-L-Ub(D)(iii) 상기 수용체 단백질의 Ub(A) 및 상기 공여체 단백질의 Ub(D)를 결합시키는 단계를 포함하고,W, X, Y 및 Z는 각각 서열번호 2의 아미노산 서열로 이루어지는 GCG 아날로그, 서열번호 12의 아미노산 서열로 이루어지는 GLP-1 아날로그, 서열번호 20의 아미노산 서열로 이루어지는 FGF21 아날로그, 서열번호 24의 아미노산 서열로 이루어지는 GIP 아날로그, 및 서열번호 27의 아미노산 서열로 이루어지는 IL-1RA로 구성된 군에서 선택되는 생체분자이고,Ub(A)는 서열번호 30의 아미노산 서열로 이루어지는 수용체 유비퀴틴이고,Ub(D)는 서열번호 31의 아미노산 서열로 이루어지는 공여체 유비퀴틴이고,L은 각각 독립적으로 부재 또는 링커 (Linker)이고,A는 캐리어 (Carrier)인 것을 특징을 하는, 단백질 결합체의 제조 방법.
- 제25항에 있어서,X는 서열번호 2의 아미노산 서열로 이루어지는 GCG 아날로그이고, Y는 서열번호 12의 아미노산 서열로 이루어지는 GLP-1 아날로그이고, Z는 서열번호 20의 아미노산 서열로 이루어지는 FGF21 아날로그이고, W는 서열번호 24의 아미노산 서열로 이루어지는 GIP 아날로그 또는 서열번호 27의 서열로 이루어지는 IL-1RA인 것을 특징으로 하는, 단백질 결합체의 제조 방법.
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/921,562 US20240066137A1 (en) | 2020-04-29 | 2021-04-29 | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes |
IL297266A IL297266A (en) | 2020-04-29 | 2021-04-29 | A new protein conjugate, and its use for the prevention or treatment of non-alcoholic steatohepatitis, obesity and diabetes |
EP21796251.3A EP4144375A1 (en) | 2020-04-29 | 2021-04-29 | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes |
JP2022564665A JP2023523288A (ja) | 2020-04-29 | 2021-04-29 | 新規なタンパク質結合体、並びにその非アルコール性脂肪性肝炎、肥満及び糖尿病の予防または治療用途 |
BR112022021765A BR112022021765A2 (pt) | 2020-04-29 | 2021-04-29 | Conjugado de proteína, composição farmacêutica, método para prevenção ou tratamento de esteato-hepatite não alcoólica, fígado gorduroso, fibrose hepática, cirrose, câncer de fígado, obesidade ou diabetes, método para preparação de um conjugado de proteína |
MX2022013175A MX2022013175A (es) | 2020-04-29 | 2021-04-29 | Conjugado de proteinas novedoso, y uso del mismo para prevenir o tratar esteatohepatitis no alcoholica, obesidad y diabetes. |
CN202180029922.3A CN115515641A (zh) | 2020-04-29 | 2021-04-29 | 新型蛋白质结合物及其非酒精性脂肪性肝炎、肥胖及糖尿病的预防或治疗用途 |
AU2021264869A AU2021264869A1 (en) | 2020-04-29 | 2021-04-29 | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes |
CA3175852A CA3175852A1 (en) | 2020-04-29 | 2021-04-29 | Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200052866 | 2020-04-29 | ||
KR10-2020-0052866 | 2020-04-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021221482A1 true WO2021221482A1 (ko) | 2021-11-04 |
Family
ID=78373739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/005481 WO2021221482A1 (ko) | 2020-04-29 | 2021-04-29 | 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20240066137A1 (ko) |
EP (1) | EP4144375A1 (ko) |
JP (1) | JP2023523288A (ko) |
KR (1) | KR20210134245A (ko) |
CN (1) | CN115515641A (ko) |
AU (1) | AU2021264869A1 (ko) |
BR (1) | BR112022021765A2 (ko) |
CA (1) | CA3175852A1 (ko) |
CL (1) | CL2022002980A1 (ko) |
IL (1) | IL297266A (ko) |
MX (1) | MX2022013175A (ko) |
WO (1) | WO2021221482A1 (ko) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7430476B2 (en) * | 2001-02-19 | 2008-09-30 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
US7491697B2 (en) * | 2003-12-10 | 2009-02-17 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US8263554B2 (en) * | 2010-06-09 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | Methods of using GLP-1 receptor agonists to treat pancreatitis |
US8454971B2 (en) * | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
KR20140142293A (ko) * | 2012-03-16 | 2014-12-11 | 제넨테크, 인크. | 조작된 입체형태적으로-안정화된 단백질 |
US9074014B2 (en) * | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
KR20160032699A (ko) | 2014-09-16 | 2016-03-24 | 한미약품 주식회사 | 지속형 glp-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도 |
KR102034607B1 (ko) | 2015-06-22 | 2019-10-22 | 일라이 릴리 앤드 캄파니 | 글루카곤 및 glp-1 공-효능제 화합물 |
KR20190139841A (ko) * | 2018-05-28 | 2019-12-18 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 링커에 결합된 선형 다기능성 멀티머 생체분자 및 이의 용도 |
-
2021
- 2021-04-29 WO PCT/KR2021/005481 patent/WO2021221482A1/ko unknown
- 2021-04-29 CA CA3175852A patent/CA3175852A1/en active Pending
- 2021-04-29 CN CN202180029922.3A patent/CN115515641A/zh active Pending
- 2021-04-29 MX MX2022013175A patent/MX2022013175A/es unknown
- 2021-04-29 KR KR1020210055849A patent/KR20210134245A/ko not_active Application Discontinuation
- 2021-04-29 AU AU2021264869A patent/AU2021264869A1/en active Pending
- 2021-04-29 IL IL297266A patent/IL297266A/en unknown
- 2021-04-29 US US17/921,562 patent/US20240066137A1/en active Pending
- 2021-04-29 EP EP21796251.3A patent/EP4144375A1/en active Pending
- 2021-04-29 BR BR112022021765A patent/BR112022021765A2/pt unknown
- 2021-04-29 JP JP2022564665A patent/JP2023523288A/ja active Pending
-
2022
- 2022-10-26 CL CL2022002980A patent/CL2022002980A1/es unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7430476B2 (en) * | 2001-02-19 | 2008-09-30 | Merck Patent Gmbh | Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity |
US7491697B2 (en) * | 2003-12-10 | 2009-02-17 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US8454971B2 (en) * | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9074014B2 (en) * | 2008-08-07 | 2015-07-07 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
US8680049B2 (en) * | 2008-12-15 | 2014-03-25 | Zealand Pharma A/S | Glucagon analogues |
US8263554B2 (en) * | 2010-06-09 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | Methods of using GLP-1 receptor agonists to treat pancreatitis |
KR20140142293A (ko) * | 2012-03-16 | 2014-12-11 | 제넨테크, 인크. | 조작된 입체형태적으로-안정화된 단백질 |
KR20160032699A (ko) | 2014-09-16 | 2016-03-24 | 한미약품 주식회사 | 지속형 glp-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도 |
KR102034607B1 (ko) | 2015-06-22 | 2019-10-22 | 일라이 릴리 앤드 캄파니 | 글루카곤 및 glp-1 공-효능제 화합물 |
KR20190139841A (ko) * | 2018-05-28 | 2019-12-18 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 링커에 결합된 선형 다기능성 멀티머 생체분자 및 이의 용도 |
Non-Patent Citations (1)
Title |
---|
METABOLISM CLINICAL AND EXPERIMENTAL, vol. 65, 2016, pages 1038 - 1048 |
Also Published As
Publication number | Publication date |
---|---|
BR112022021765A2 (pt) | 2022-12-13 |
MX2022013175A (es) | 2022-11-30 |
AU2021264869A1 (en) | 2022-12-01 |
EP4144375A1 (en) | 2023-03-08 |
KR20210134245A (ko) | 2021-11-09 |
CN115515641A (zh) | 2022-12-23 |
CL2022002980A1 (es) | 2023-06-23 |
CA3175852A1 (en) | 2021-11-04 |
US20240066137A1 (en) | 2024-02-29 |
JP2023523288A (ja) | 2023-06-02 |
IL297266A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017116205A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
WO2012173422A9 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
WO2018056764A1 (ko) | 인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도 | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2011142514A1 (ko) | Pias3을 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 | |
WO2018174668A2 (ko) | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 | |
WO2019066570A1 (ko) | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 | |
WO2021182898A1 (ko) | 신규한 화합물을 포함하는 항당뇨 및 항비만용 조성물 | |
WO2021066600A1 (ko) | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 | |
WO2021221482A1 (ko) | 신규한 단백질 결합체, 및 이의 비알콜성 지방간염, 비만 및 당뇨 질환의 예방 또는 치료 용도 | |
EP1756156B1 (en) | Selective vpac2 receptor peptide agonists | |
WO2022015115A1 (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
WO2021107519A1 (en) | Biotin moiety-conjugated polypeptide and pharmaceutical composition for oral administration comprising the same | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2022139493A1 (ko) | TGF-β 신호전달을 억제할 수 있는 신규한 펩타이드 및 이의 용도 | |
WO2020242268A1 (ko) | 비오틴 모이어티와 결합된 생리활성 물질 및 이를 포함하는 경구 투여용 조성물 | |
WO2021215801A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 | |
WO2020263063A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도 | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2020214013A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 | |
WO2019035672A1 (ko) | 아실화 옥신토모듈린 펩타이드 유사체 | |
WO2022035271A1 (ko) | 삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물 | |
WO2021235916A1 (ko) | 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제 | |
WO2021157973A1 (ko) | 페길화된 ige-의존적 히스타민 방출인자(hrf) 결합 펩타이드 및 이의 용도 | |
WO2022035302A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21796251 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3175852 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022564665 Country of ref document: JP Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022021765 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021264869 Country of ref document: AU Date of ref document: 20210429 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021796251 Country of ref document: EP Effective date: 20221129 |
|
ENP | Entry into the national phase |
Ref document number: 112022021765 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221026 |